Clinical trial
A Phase 3, Randomized, Double-Blind Clinical Trial to Evaluate the Efficacy and Safety of Abatacept SC With Standard Treatment Compared to Standard Treatment Alone in Improving Disease Activity in Adults With Active Idiopathic Inflammatory Myopathy (IIM)
NCT02971683 is registered in ClinicalTrials.gov with Bristol-Myers Squibb as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, Randomized, Double-Blind Clinical Trial to Evaluate the Efficacy and Safety of Abatacept SC With Standard Treatment Compared to Standard Treatment Alone in Improving Disease Activity in Adults With Active Idiopathic Inflammatory Myopathy (IIM)
- Lead sponsor
- Bristol-Myers Squibb
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- May 4, 2017
- Completion date
- August 2, 2022
- Enrollment
- 149 (actual)
- Sites
- 79
Conditions
As the registry lists them; a condition with its own page is linked.
autoimmune necrotizing myopathy, dermatomyositis, juvenile myositis above the age of 18, overlap myositis, polymyositis